New combo attack on tough liver cancer shows promise in Real-World study
NCT ID NCT07272265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 300 adults with high-risk liver cancer who received a combination of two drugs (atezolizumab and bevacizumab) plus chemotherapy infused directly into the liver artery. The goal was to see how well this treatment worked and how safe it was in everyday medical practice. The study is already completed, and researchers are analyzing survival and tumor progression data from medical records across 10 hospitals in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs) plus liver artery infusion of FOLFOX chemotherapy
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment option for patients with high-risk liver cancer that has spread to major blood vessels or bile ducts.
- What could go wrong
- This is a retrospective study, not a controlled trial, so results may be less reliable. The combination also carries risks of serious side effects from both immunotherapy and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?